Jim Joyce Chairman, CEO January 9, 2012My presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whetherand when our products are successfully developed and introduced, market acceptance of the Aethlon ADAPT™ system, the Hemopuriﬁer® andother product offerings, regulatory delays, manufacturing delays, and other risks detailed in our sec ﬁlings accessible at www. Sec.gov.
We create medical devices to address unmetmedical needs in cancer, infectious disease,and other life-threatening conditions
The transition from development-stage to revenue-stage organization
Aethlon ADAPT™ therapies seamlessly integrateinto the infrastructure of dialysis and CRRTmachines located in hospitals in clinics worldwide
Aethlon ADAPT™ therapies provide access to the entire circulatory system• Rapid real-time access to single or multiple therapeutic targets in as little as 15 minutes• Adjunct to improve SOC therapy beneﬁt without adding drug toxicity or interaction risks• Able to address targets beyond the reach of drugs
The Aethlon Hemopuriﬁer®• The lead Aethlon ADAPT™ treatment candidate• Broad-spectrum capture of viral pathogens and immunosuppressive exosomes underlying cancer and infectious disease• Compelling HCV & HIV/AIDS treatment outcomes in ESRD patient population
• The Drug Industry • Provides medical device pathway for afﬁnity drug agents • $5 million vs. $500 million • Repurposes approved, clinical stage & previous clinical dropouts• Military & Government Health Agencies • Seeking innovative therapeutic solutions